2. Signaling Pathways
  3. Immunology/Inflammation
  4. C-type Lectin-like Receptors (CTLRs)

C-type Lectin-like Receptors (CTLRs)

C-type Lectin-like Receptors (CTLRs)

C-type Lectin-like Receptors (CTLRs) are a class of protein receptors that contain a C-type lectin-like domain but do not necessarily rely on calcium ions to recognize ligands. They are usually classified as activating or inhibitory receptors, based on their intracellular signaling motifs. CTLRs are capable of recognizing pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), and play important roles in innate and adaptive immunity. After binding to ligands, CLRs act as antigen-uptake receptors, internalize antigens and present them to T cells, and activate multiple signaling pathways such as NF-κB, IFN, and inflammasomes to regulate the functions of immune cells. Abnormal expression or function of CLRs is closely related to cancer, infectious diseases, autoimmune diseases, and others[1][2].

C-type Lectin-like Receptors (CTLRs) Related Products (64):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-147295
    Odetiglucan
    		Agonist
    Odetiglucan is a novel β-glucan that is a potent immunostimulant and a Dectin-1 (CLEC7A) agonist. Odetiglucan activates innate immune effector cells and triggers a coordinated anti-cancer immune response.
    Odetiglucan
  • HY-119109
    Laminaran
    		Ligand
    Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.
    Laminaran
  • HY-131166
    Curdlan
    		Activator 98.5%
    Curdlan is a polysaccharide found in bacteria, consisting of a glucose homopolymer with β-1,3-glycosidic linkages. Curdlan can be recognized by Dectin-1 (a C-type lectin receptor), inducing immune responses in tissue mast cells and enhancing dendritic cell effects in tumor immunity. Curdlan holds potential for research in cancer and immune-inflammatory diseases.
    Curdlan
  • HY-131166
    Curdlan
    		Ligand 98.5%
    Curdlan is a polysaccharide found in bacteria, consisting of a glucose homopolymer with β-1,3-glycosidic linkages. Curdlan can be recognized by Dectin-1 (a C-type lectin receptor), inducing immune responses in tissue mast cells and enhancing dendritic cell effects in tumor immunity. Curdlan holds potential for research in cancer and immune-inflammatory diseases.
    Curdlan
  • HY-P992138
    Vadalentamig
    		Inhibitor
    Vadalentamig is a human-derived bispecific antibody targeting NKG2D/CD314&ERBB1/EGFR/HER1.
    Vadalentamig
  • HY-P991818
    Anti-Mouse CD370 Antibody (1F6)
    		Inhibitor
    Anti-Mouse CD370 Antibody (1F6) reacts with the mouse CD370 (also known as CLEC9A or DNGR1). CD370 is a type II membrane protein with a single extracellular C-type lectin domain. Recommend Isotype Controls: Rat IgG1 kappa, Isotype Control (HY-P99979).
    Anti-Mouse CD370 Antibody (1F6)
  • HY-P992391
    IPH4301
    		Inhibitor
    IPH4301 is a monoclonal antibody targeting MICA/B, with dual activities of cytotoxicity and immunoregulation. IPH4301 blocks the interaction between MICA/B and NKG2D, inhibits their hydrolysis into soluble sMICA/B, and mediates antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis against tumor cells expressing MICA/MICB. IPH4301 restores the expression and function of NKG2D on primary NK cells and T cells, reverses the immunosuppression induced by M2 macrophages, and enhances NK cell-mediated tumor cell apoptosis. IPH4301 can be used in research related to cancer and triple-negative breast cancer.
    IPH4301
  • HY-134816
    D-Glucan
    		Agonist
    D-Glucan is an orally effective Dectin-1 receptor immune activator with antioxidant properties (reducing TNF-α). D-Glucan activates macrophages and neutrophils to scavenge free radicals, inhibit oxidative stress and inflammatory responses, and improve insulin sensitivity. D-Glucan promotes glycolysis by enhancing the activity of the antioxidant enzyme glutathione, inhibiting gluconeogenesis and activating GK. D-Glucan can be used in the research of liver damage protection (antagonizing Acetaminophen (HY-66005) toxicity), radiation protection (synergistic with vitamin E) and diabetes (improving glucose metabolism).
    D-Glucan
  • HY-139413
    β-D-Glucan
    		Ligand 99.00%
    β-D-glucan is a natural non-digestible polysaccharide and high biocompatibility that can be selectively recognized by recognition receptors such as Dectin-1 and Toll-like receptors as well as being easily internalized by murine or human macrophages, which is likely to attribute to a target delivery. β-d-glucan is an enteric delivery vehicle for probiotics.
    β-D-Glucan
  • HY-112137
    Trehalose-6,6'-dibehenate
    		Activator 99.92%
    Trehalose-6,6'-dibehenate is an orally active glycolipid. Trehalose-6,6'-dibehenate activates Mincle and inflammasome, inducing IL-1β secretion in a caspase activity-dependent manner. Trehalose-6,6'-dibehenate exerts a Myd88-dependent adjuvant activity. Trehalose-6,6'-dibehenate induces Th-1/Th-17 immune responses.
    Trehalose-6,6'-dibehenate
  • HY-P9990
    Litifilimab
    		Inhibitor 99.51%
    Litifilimab (BIIB059) is a humanized anti-BDCA2 IgG1 monoclonal antibody administered subcutaneously. Litifilimab can inhibit the production of type I interferons, cytokines and chemokines. Litifilimab can be used in the research of diseases such as systemic lupus erythematosus.
    Litifilimab
  • HY-159069
    Zymosan (ZM), 95%
    		Ligand
    Zymosan (ZM), 95% is a yeast cell wall-derived carbohydrate-rich preparation and immunomodulator. Zymosan (ZM), 95% binds to and activates TLR-2, TLR-4, and Dectin-1 receptor to trigger downstream signaling pathways. Zymosan (ZM), 95% upregulates TLR-2, TLR-4, and TNF-α mRNA expression, increases serum TNF-α levels, and stimulates splenocyte number and viability in mice. Zymosan (ZM), 95% attenuates melanoma growth progression, modulates macrophage marker gene expression, and mediates phagocytosis, ROS generation, and cytokine production. Zymosan (ZM), 95% reduces Connexin 43 protein and mRNA levels, inhibits gap junctional intercellular communication, and induces proinflammatory factor production in human corneal cells. Zymosan (ZM), 95% induces peritoneal inflammation in mice, functions as a drug carrier, and supports fibroblast cell attachment in hydrogel formulations. Zymosan (ZM), 95% can be used for the research of melanoma, tumors, fungal keratitis, ocular surface inflammatory disorders, and peritoneal inflammation.
    Zymosan (ZM), 95%
  • HY-P990026
    Ulviprubart
    		Modulator 99.39%
    Ulviprubart (ABC-008) is a monoclonal antibody targeting the KLRG1 receptor that selectively depletes highly differentiated cytotoxic T cells. Ulviprubart can be used in the study of inclusion body myositis (IBM).
    Ulviprubart
  • HY-P99389
    Tesnatilimab
    		99.80%
    Tesnatilimab (JNJ-64304500) is a human IgG4 monoclonal antibody targeting NKG2D, with a KD value of 9.2 pM. Tesnatilimab blocks the binding of ligands to the NKG2D receptor, thereby inhibiting downstream proinflammatory cytokine, cytotoxic mediator signaling pathways and proinflammatory immune responses. Tesnatilimab is applicable to research related to Crohn's disease.
    Tesnatilimab
  • HY-N0434
    Astragaloside III
    		Activator 99.70%
    Astragaloside III is a triterpenoid saponin. Astragaloside III can be extracted from Astragalus root. Astragaloside III increases NKG2D and induces TACE phosphorylation. Astragaloside III induces Apoptosis. Astragaloside III has antiviral activity against dengue serotypes 1 and 3. Astragaloside III has anticancer activity against breast and colon cancer.
    Astragaloside III
  • HY-P991175
    Anti-Dectin-1 Antibody (2M24)
    		Inhibitor
    Anti-Dectin-1 Antibody (2M24) is a humanized IgG1 monoclonal antibody that targets Dectin-1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-Dectin-1 Antibody (2M24)
  • HY-P990178
    Anti-Mouse NKG2D/CD314 Antibody (CX5)
    Anti-Mouse NKG2D/CD314 Antibody (CX5) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse NKG2D/CD314. Anti-Mouse NKG2D/CD314 Antibody (CX5) reduces cytotoxicity of natural killer cells. Anti-Mouse NKG2D/CD314 Antibody (CX5) can be used for the researches of cancer, infection, inflammation, immunology and metabolic disease, such as colitis and diabetes.
    Anti-Mouse NKG2D/CD314 Antibody (CX5)
  • HY-165126
    Schizophyllan
    		Ligand
    Schizophyllan (SPG) is an orally active extracellular β-glucan produced by the fungus Schizophyllum commune. Schizophyllan improves mitochondrial function and protects against metabolic liver injury by activating the SIRT3 pathway. Schizophyllan inhibits osteoclastogenesis and promotes osteoblast differentiation by suppressing the phosphorylation of JNK/p38, as well as downregulating PGC1β/PPARγ, c-Fos and NFATc1. Recognized via Dectin-1, schizophyllan enables precise delivery of oligonucleotide drugs and antigens to antigen-presenting cells, thus holding great potential in the treatment of inflammatory diseases and vaccine development.
    Schizophyllan
  • HY-N15135
    Arabinoxylan (Medium viscosity)
    		Modulator
    Arabinoxylan Medium viscosity is an orally active Dectin-1 splice variant modulator, glucose absorption inhibitor, and chyme viscosity enhancer. Arabinoxylan Medium viscosity inhibits particulate β-glucan-induced Dectin-1A activation and mildly suppresses Dectin-1B activation. In human dendritic cells stimulated with particulate β-glucan, Arabinoxylan Medium viscosity reduces the production of IL-10 and TNF-α, and increases the production of IL-4 and IL-23. Arabinoxylan Medium viscosity also supports antifungal immune responses without activating TLR2, TLR4 or TLR5, and does not induce cytokine production when used to stimulate human dendritic cells alone. Arabinoxylan Medium viscosity increases small intestinal chyme viscosity, gets degraded in the large intestine to produce short-chain fatty acids, reduces glucose absorption and insulin response, and improves glucose homeostasis. Arabinoxylan Medium viscosity supports microbial fermentation and the growth of beneficial microbiota in the gastrointestinal tract, prevents bile acid reabsorption, and delays starch digestion. Arabinoxylan Medium viscosity can be used in research related to type 2 diabetes, impaired glucose tolerance, and metabolic syndrome.
    Arabinoxylan (Medium viscosity)
  • HY-N10634
    D-Glucosyl-β-1,1′-N-palmitoylsphingosine
    		Ligand 99.30%
    D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl (β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand with immunostimulatory activity. D-Glucosyl-β-1,1′-N-palmitoylsphingosine binds to and activates macrophage-inducible C-type lectin (Mincle). D-Glucosyl-β-1,1′-N-palmitoylsphingosine is applicable to the research of immune system diseases.
    D-Glucosyl-β-1,1′-N-palmitoylsphingosine